Loading...
XSHG
603079
Market cap304mUSD
Jul 09, Last price  
10.94CNY
1D
-2.15%
1Q
-34.57%
IPO
-10.28%
Name

Zhejiang Shengda Bio-pharm Co Ltd

Chart & Performance

D1W1MN
XSHG:603079 chart
P/E
33.27
P/S
2.45
EPS
0.33
Div Yield, %
0.55%
Shrs. gr., 5y
1.03%
Rev. gr., 5y
-0.53%
Revenues
845m
+2.07%
449,254,400398,770,700380,897,100536,429,499482,147,680508,561,120492,709,860519,149,812867,314,752789,732,754738,019,049727,405,727827,401,959844,536,869
Net income
62m
+111.24%
52,360,20054,591,70043,785,10086,702,90060,935,62172,610,20744,544,42547,030,269197,438,34175,756,47631,484,429-54,062,93129,424,49362,155,711
CFO
139m
-6.08%
110,080,900105,279,80034,401,628148,071,83973,001,50495,334,03188,685,91258,553,623333,201,87574,460,43940,717,54664,421,472147,878,103138,884,551
Dividend
Jun 12, 20240.06 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Zhejiang Shengda Bio-Pharm Co., Ltd., based in Tiantai, China, is a global enterprise dedicated to the research, development, manufacturing, and distribution of a diverse range of food and animal feed additives. The company's comprehensive product portfolio includes essential vitamins like biotin and folic acid, biological preservation agents such as nisin and natamycin, and intermediate Active Pharmaceutical Ingredients (APIs). They also provide various natural solutions for food preservation.
IPO date
Aug 23, 2017
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT